Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 556 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07325721RecruitingPhase 2
Shorter radiation with a focused boost for high-risk prostate cancer
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Charleston, South CarolinaAges 18 years+ - NCT07337421RecruitingPhase 2
Chemo infusion after liver cancer surgery to lower recurrence risk
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Yangzhou, JiangsuAges 18–75 - NCT07337460RecruitingPhase 2
Icaritin plus chemotherapy for high-risk liver cancer after surgery
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
Yangzhou, JiangsuAges 18–75 - NCT07501117RecruitingPhase 1
Immunotherapy before eye removal for high-risk eye melanoma
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
Herlev, HerlevAges 18–80 - NCT07348042RecruitingPhase 1
Study of RGL-270 with or without Adebelimab for high-risk solid tumors
This trial tests a new treatment (RGL-270) alone or with another drug (Adebelimab) to prevent cancer from coming back after surgery. It is for people with solid tumors that have a high chance of returning.
ShanghaiAges 18–75 - NCT07349069RecruitingPhase 3
HRS-8080 vs. standard hormone therapy for early breast cancer
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT07370246Recruiting
Carotid stenting for high-risk carotid surgery patients
This trial tests whether placing a stent in the narrowed carotid artery is a good option for people who are at high risk for the standard surgery (carotid endarterectomy). If you have significant blockages in your neck arteries and certain health or anatomical factors that make surgery riskier, this study may be for you.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02605421RecruitingPhase 2
High-risk neuroblastoma stem cell treatment after initial response
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Minneapolis, MinnesotaAges Up to 30 years - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT07527689Recruiting
Faster vs. Standard Radiation After Breast Cancer Surgery
This study compares two radiation schedules for breast cancer patients at high risk of cancer returning in lymph nodes. Both use modern radiation therapy, but one delivers treatment faster (ultra-hypofractionated) while the other uses a more moderate schedule. The goal is to see which approach works better with fewer side effects.
ShanghaiAges 18 years+ - NCT07417397RecruitingPhase 3
TACE after surgery for high-risk liver cancer
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
NanningAges 18–70 - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07428993RecruitingPhase 2
CAR T-Cell Therapy for High-Risk Osteosarcoma
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07452991Recruiting
Ultrasound-guided clot-busting for moderate-risk pulmonary embolism
This trial tests a procedure that uses ultrasound to guide a catheter that delivers clot-dissolving medicine directly to a blood clot in the lungs. It is for people who have a pulmonary embolism that causes some heart strain but who are not in shock.
MoscowAges 18 years+ - NCT07460362RecruitingPhase 2
Glofitamab and lenalidomide for high-risk mantle cell lymphoma
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Beijing, Beijing MunicipalityAges 18–80 - NCT07461415Recruiting
Telehealth coaching for high-risk hypertension
This trial tests whether community health workers can help people with very high blood pressure manage it better through phone calls and home visits. It may help you if you have had a dangerously high blood pressure reading in the emergency room but do not have serious organ damage.
Karachi, SindhAges 18 years+ - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75 - NCT07480785Recruiting
Nerve stimulation plus 3 anti-nausea drugs for surgery nausea
This trial tests whether combining a gentle electrical nerve stimulation technique (called TEAS) with three standard anti-nausea medicines can better prevent nausea and vomiting after laparoscopic surgery in women at high risk. If you qualify, you would receive the stimulation plus the medicines, or the medicines alone, to see which works best.
Hangzhou, ZhejiangAges 18–65 - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 556 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.